R. Masgrau, C. Guaza, R. Ransohoff, and E. Galea, Should We Stop Saying ???Glia??? and ???Neuroinflammation????, Trends in Molecular Medicine, vol.23, issue.6, pp.486-500, 2017.
DOI : 10.1016/j.molmed.2017.04.005

M. Schwartz and A. Deczkowska, Neurological Disease as a Failure of Brain???Immune Crosstalk: The Multiple Faces of Neuroinflammation, Trends in Immunology, vol.37, issue.10, pp.668-79, 2016.
DOI : 10.1016/j.it.2016.08.001

D. Kempuraj, R. Thangavel, G. Selvakumar, S. Zaheer, M. Ahmed et al., Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration, Frontiers in Cellular Neuroscience, vol.9, 2017.
DOI : 10.2147/ndt.s48455

M. Lyman, D. Lloyd, J. X. Vizcaychipi, M. Ma, and D. , Neuroinflammation: The role and consequences, Neuroscience Research, vol.79, 2014.
DOI : 10.1016/j.neures.2013.10.004

T. Kielian, Multifaceted roles of neuroinflammation: the need to consider both sides of the coin, Journal of Neurochemistry, vol.86, issue.Suppl. 1, pp.5-9, 2016.
DOI : 10.1002/jnr.21730

E. Wohleb and J. Godbout, Basic Aspects of the Immunology of Neuroinflammation, Mod Trends Pharmacopsychiatry, vol.28, pp.1-19, 2013.
DOI : 10.1159/000343964

M. Yepes, TWEAK and Fn14 in the Neurovascular Unit, Frontiers in Immunology, vol.4, 2013.
DOI : 10.3389/fimmu.2013.00367

M. Pekny, U. Wilhelmsson, and M. Pekna, The dual role of astrocyte activation and reactive gliosis, Neuroscience Letters, vol.565, pp.30-38, 2014.
DOI : 10.1016/j.neulet.2013.12.071

L. Pinheiro, M. Kooij, G. Mizee, M. Kamermans, A. Enzmann et al., Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1862, issue.3, pp.461-71, 2016.
DOI : 10.1016/j.bbadis.2015.10.018

J. Rustenhoven, D. Jansson, L. Smyth, and M. Dragunow, Brain Pericytes As Mediators of Neuroinflammation, Trends in Pharmacological Sciences, vol.38, issue.3, pp.291-304, 2017.
DOI : 10.1016/j.tips.2016.12.001

B. Becher, S. Spath, and J. Goverman, Cytokine networks in neuroinflammation, Nature Reviews Immunology, vol.72, issue.1, pp.49-59, 2017.
DOI : 10.1097/NEN.0b013e3182909f2f

L. Burkly, J. Michaelson, K. Hahm, A. Jakubowski, and T. Zheng, TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease, Cytokine, vol.40, issue.1, 2007.
DOI : 10.1016/j.cyto.2007.09.007

R. Echeverry, F. Wu, W. Haile, J. Wu, and M. Yepes, The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system, Journal of Neuroinflammation, vol.105, issue.1, pp.45-55, 2012.
DOI : 10.1073/pnas.0801447105

L. Burkly and . Tweak, TWEAK/Fn14 axis: The current paradigm of tissue injury-inducible function in the midst of complexities, Seminars in Immunology, vol.26, issue.3, pp.229-265, 2014.
DOI : 10.1016/j.smim.2014.02.006

M. Bowerman, C. Salsac, E. Coque, É. Eiselt, R. Deschaumes et al., Tweak regulates astrogliosis, microgliosis and skeletal muscle atrophy in a mouse model of amyotrophic lateral sclerosis, Human Molecular Genetics, vol.35, issue.6, pp.3440-56, 2015.
DOI : 10.1016/S0896-6273(02)00905-4

Y. Chicheportiche, P. Bourdon, H. Xu, Y. Hsu, H. Scott et al., TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis, Journal of Biological Chemistry, vol.3, issue.51, pp.32401-32411, 1997.
DOI : 10.1016/0966-842X(94)90539-8

M. Nakayama, N. Kayagaki, N. Yamaguchi, K. Okumura, and H. Yagita, Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity, J Exp Med, vol.192, issue.9, 2000.

S. Desplat-jégo, L. Feuillet, R. Creidy, I. Malikova, R. Rance et al., TWEAK is expressed at the cell surface of monocytes during multiple sclerosis, Journal of Leukocyte Biology, vol.85, issue.1, pp.132-137, 2009.
DOI : 10.1189/jlb.0608347

H. Maecker, E. Varfolomeev, F. Kischkel, D. Lawrence, H. Leblanc et al., TWEAK Attenuates the Transition from Innate to Adaptive Immunity, Cell, vol.123, issue.5, pp.931-975, 2005.
DOI : 10.1016/j.cell.2005.09.022

A. Wicovsky, S. Salzmann, C. Roos, M. Ehrenschwender, T. Rosenthal et al., TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling, Cell Death & Differentiation, vol.268, issue.11, pp.1445-5980, 2009.
DOI : 10.1038/ni.1678

M. Bhattacharjee, R. Raju, A. Radhakrishnan, V. Nanjappa, B. Muthusamy et al., A Bioinformatics Resource for TWEAK-Fn14 Signaling Pathway, Journal of Signal Transduction, vol.2011, issue.4, p.376470, 2012.
DOI : 10.1007/s00296-010-1640-x
URL : https://doi.org/10.1155/2012/376470

L. Burkly, Regulation of Tissue Responses: The TWEAK/Fn14 Pathway and Other TNF/TNFR Superfamily Members That Activate Non-Canonical NF??B Signaling, Frontiers in Immunology, vol.5, 2015.
DOI : 10.3389/fimmu.2014.00511

C. Roos, A. Wicovsky, N. Müller, S. Salzmann, T. Rosenthal et al., Soluble and Transmembrane TNF-Like Weak Inducer of Apoptosis Differentially Activate the Classical and Noncanonical NF-??B Pathway, The Journal of Immunology, vol.185, issue.3, pp.1593-605, 2010.
DOI : 10.4049/jimmunol.0903555

S. Desplat-jégo, S. Varriale, R. Creidy, R. Terra, D. Bernard et al., TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity, Journal of Neuroimmunology, vol.133, issue.1-2, pp.116-139, 2002.
DOI : 10.1016/S0165-5728(02)00368-5

P. Saas, J. Boucraut, P. Walker, A. Quiquerez, M. Billot et al., TWEAK stimulation of astrocytes and the proinflammatory consequences, 1<102::AID- GLIA100>3.0.CO, pp.102-109, 2000.
DOI : 10.4049/jimmunol.164.3.1277

E. Rousselet, S. Traver, Y. Monnet, A. Perrin, N. Mandjee et al., Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Induces Astrocyte Proliferation through the Activation of Transforming-Growth Factor-??/Epidermal Growth Factor Receptor Signaling Pathway, Molecular Pharmacology, vol.82, issue.5, pp.948-57, 2012.
DOI : 10.1124/mol.112.079608

D. Stephan, O. Sbai, J. Wen, P. Couraud, C. Putterman et al., TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier, Journal of Neuroinflammation, vol.41, issue.Pt 2, pp.9-10, 2013.
DOI : 10.3109/08820139.2011.604863
URL : https://hal.archives-ouvertes.fr/inserm-00787290

A. Nazeri, P. Heydarpour, S. Sadaghiani, M. Sahraian, and L. Burkly, A Further TWEAK to Multiple Sclerosis Pathophysiology, Molecular Neurobiology, vol.166, issue.2, pp.78-87, 2014.
DOI : 10.1016/S0002-9440(10)62273-0

B. Serafini, R. Magliozzi, B. Rosicarelli, R. Reynolds, T. Zheng et al., Expression of TWEAK and Its Receptor Fn14 in the Multiple Sclerosis Brain: Implications for Inflammatory Tissue Injury, Journal of Neuropathology & Experimental Neurology, vol.67, issue.12, pp.1137-1185, 2008.
DOI : 10.1002/glia.20208

H. Iocca, S. Plant, Y. Wang, L. Runkel, O. Connor et al., TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model, Journal of Neuroimmunology, vol.194, issue.1-2, pp.97-106, 2008.
DOI : 10.1016/j.jneuroim.2007.12.003

S. Desplat-jégo, R. Creidy, S. Varriale, N. Allaire, Y. Luo et al., Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis, Clinical Immunology, vol.117, issue.1, pp.15-23, 2005.
DOI : 10.1016/j.clim.2005.06.005

M. Razmara, B. Hilliard, A. Ziarani, R. Murali, S. Yellayi et al., Fn14-TRAIL, a Chimeric Intercellular Signal Exchanger, Attenuates Experimental Autoimmune Encephalomyelitis, The American Journal of Pathology, vol.174, issue.2, pp.460-74080462, 2009.
DOI : 10.2353/ajpath.2009.080462
URL : http://europepmc.org/articles/pmc2630555?pdf=render

H. Prinz-hadad, T. Mizrachi, M. Irony-tur-sinai, T. Prigozhina, A. Aronin et al., Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14??TRAIL, Journal of Neuroinflammation, vol.249, issue.Suppl 6, pp.36-46, 2013.
DOI : 10.1007/s004150200067

A. Mueller, X. Pedré, I. Kleiter, M. Hornberg, A. Steinbrecher et al., Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis, Journal of Neuroimmunology, vol.159, issue.1-2, pp.55-65, 2005.
DOI : 10.1016/j.jneuroim.2004.10.001

B. Van-oosten, F. Barkhof, L. Truyen, J. Boringa, F. Bertelsmann et al., Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2, Neurology, vol.47, issue.6, pp.1531-1535, 1996.
DOI : 10.1212/WNL.47.6.1531

J. Chen, L. Wei, and Y. Xia, Roles of tumour necrosis factor-related weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in lupus nephritis, Nephrology, vol.82, issue.Suppl 1, pp.101-107, 2017.
DOI : 10.1111/bcp.12914

J. Wen, Y. Xia, A. Stock, J. Michaelson, L. Burkly et al., Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway, Journal of Autoimmunity, vol.43, pp.44-54, 2013.
DOI : 10.1016/j.jaut.2013.03.002

A. Stock, J. Wen, and C. Putterman, Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway, Frontiers in Immunology, vol.4, 2013.
DOI : 10.3389/fimmu.2013.00484

J. Wen, C. Chen, A. Stock, J. Doerner, M. Gulinello et al., Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in Boulamery and Desplat-Jégo TWEAK/Fn14 in NI Regulation Frontiers in Immunology | www.frontiersin, 1534.

J. Wen, J. Doerner, K. Weidenheim, Y. Xia, A. Stock et al., TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice, Journal of Autoimmunity, vol.60, pp.40-50, 2015.
DOI : 10.1016/j.jaut.2015.03.005

E. Trysberg, K. Blennow, O. Zachrisson, and A. Tarkowski, Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement, Arthritis Research & Therapy, vol.6, issue.6, pp.551-557, 1228.
DOI : 10.1186/ar1228

E. Trysberg, L. Su, J. Michaelson, and C. Putterman, Cerebrospinal fluid (CSF) TWEAK: a novel biomarker for neuropsychiatric SLE?, Arthritis Rheum, vol.56, p.750, 2007.

H. Fragoso-loyo, Y. Atisha-fregoso, C. Nuñez-alvarez, and L. Llorente, Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erhytematosus, Lupus, vol.23, issue.4, pp.364-373, 2016.
DOI : 10.1186/1742-2094-10-9

I. Potrovita, W. Zhang, L. Burkly, K. Hahm, J. Lincecum et al., Tumor Necrosis Factor-Like Weak Inducer of Apoptosis-Induced Neurodegeneration, Journal of Neuroscience, vol.24, issue.38, pp.8237-8281, 2004.
DOI : 10.1523/JNEUROSCI.1089-04.2004

R. Polavarapu, M. Gongora, J. Winkles, and M. Yepes, Tumor Necrosis Factor-Like Weak Inducer of Apoptosis Increases the Permeability of the Neurovascular Unit through Nuclear Factor-??B Pathway Activation, Journal of Neuroscience, vol.25, issue.44, pp.10094-100, 2005.
DOI : 10.1523/JNEUROSCI.3382-05.2005

X. Zhang, J. Winkles, M. Gongora, R. Polavarapu, J. Michaelson et al., TWEAK???Fn14 Pathway Inhibition Protects the Integrity of the Neurovascular Unit during Cerebral Ischemia, Journal of Cerebral Blood Flow & Metabolism, vol.19, issue.3, pp.534-578, 2007.
DOI : 10.1038/sj.jcbfm.9600004

W. Haile, R. Echeverry, J. Wu, and M. Yepes, The Interaction between Tumor Necrosis Factor-Like Weak Inducer of Apoptosis and its Receptor Fibroblast Growth Factor-Inducible 14 Promotes the Recruitment of Neutrophils into the Ischemic Brain, Journal of Cerebral Blood Flow & Metabolism, vol.513, issue.6, pp.1147-56280, 2009.
DOI : 10.1179/016164104X2357

M. Yepes, S. Brown, E. Moore, E. Smith, D. Lawrence et al., A Soluble Fn14-Fc Decoy Receptor Reduces Infarct Volume in a Murine Model of Cerebral Ischemia, The American Journal of Pathology, vol.166, issue.2, pp.511-531, 2005.
DOI : 10.1016/S0002-9440(10)62273-0

I. Inta, K. Frauenknecht, H. Dörr, P. Kohlhof, T. Rabsilber et al., Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke, Journal of the Neurological Sciences, vol.275, issue.1-2, pp.117-137, 2008.
DOI : 10.1016/j.jns.2008.08.005

N. Tran, W. Mcdonough, P. Donohue, J. Winkles, T. Berens et al., The Human Fn14 Receptor Gene Is Up-Regulated in Migrating Glioma Cells in Vitro and Overexpressed in Advanced Glial Tumors, The American Journal of Pathology, vol.162, issue.4, pp.1313-1334, 2003.
DOI : 10.1016/S0002-9440(10)63927-2

N. Tran, W. Mcdonough, B. Savitch, S. Fortin, J. Winkles et al., Increased Fibroblast Growth Factor-Inducible 14 Expression Levels Promote Glioma Cell Invasion via Rac1 and Nuclear Factor-??B and Correlate with Poor Patient Outcome, Cancer Research, vol.66, issue.19, pp.9535-9577, 2006.
DOI : 10.1158/0008-5472.CAN-06-0418

V. Pelekanou, G. Notas, M. Kampa, E. Tsentelierou, E. Stathopoulos et al., Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis, PLoS One, vol.8, issue.12, 2013.

S. Fortin, M. Ennis, C. Schumacher, C. Zylstra-diegel, B. Williams et al., Cdc42 and the Guanine Nucleotide Exchange Factors Ect2 and Trio Mediate Fn14-Induced Migration and Invasion of Glioblastoma Cells, Molecular Cancer Research, vol.10, issue.7, pp.958-68, 2012.
DOI : 10.1158/1541-7786.MCR-11-0616

H. Dhruv, T. Whitsett, N. Jameson, F. Patel, J. Winkles et al., Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation, Carcinogenesis, vol.35, issue.1, pp.218-244, 2014.
DOI : 10.1016/j.tips.2011.11.002

E. Cherry, D. Lee, J. Jung, and R. Sitcheran, Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-??B-inducing kinase (NIK) and noncanonical NF-??B signaling, Molecular Cancer, vol.14, issue.1, pp.9-10, 2015.
DOI : 10.1128/MCB.00578-08

J. Perez, N. Tran, M. Rosenblum, C. Schneider, N. Connolly et al., The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics, Oncogene, vol.6, issue.17, pp.2145-55, 2016.
DOI : 10.1126/scisignal.2004088

A. Roos, H. Dhruv, I. Mathews, L. Inge, S. Tuncali et al., Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells, Oncotarget, vol.8, issue.7, pp.12234-12280, 2017.
DOI : 10.18632/oncotarget.14685

C. Glass, K. Saijo, B. Winner, M. Marchetto, and F. Gage, Mechanisms Underlying Inflammation in Neurodegeneration, Cell, vol.140, issue.6, pp.918-952, 2010.
DOI : 10.1016/j.cell.2010.02.016
URL : https://doi.org/10.1016/j.cell.2010.02.016

H. Liu, D. Lin, H. Xiang, W. Chen, S. Zhao et al., The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors, Experimental and Therapeutic Medicine, vol.14, issue.2, pp.891-898, 2017.
DOI : 10.3892/etm.2017.4600

C. Baiguera, M. Alghisi, A. Pinna, A. Bellucci, D. Luca et al., Late-onset Parkinsonism in NF??B/c-Rel-deficient mice, Brain, vol.19, issue.6, pp.2750-65, 2012.
DOI : 10.1096/fj.04-2751com
URL : https://academic.oup.com/brain/article-pdf/135/9/2750/933747/aws193.pdf

S. Mustafa, H. Martin, L. Burkly, A. Costa, M. Martins et al., The role of TWEAK/Fn14 signaling in the MPTP-model of Parkinson???s disease, Neuroscience, vol.319, pp.116-138, 2016.
DOI : 10.1016/j.neuroscience.2016.01.034

T. Yaylac?, E. Yüksel, R. Ünal, K. Altunsoy, N. Cingi et al., TNF-related weak inducer of apoptosis (TWEAK) levels in schizophrenia, Psychiatry Research, vol.229, issue.3, pp.755-764, 2015.
DOI : 10.1016/j.psychres.2015.08.006

M. Cingi-yirün, O. Yirün, K. Ünal, R. Yüksel, N. Altunsoy et al., Serum TNF-related weak inducer of apoptosis (TWEAK) and TNF-related apoptosis-inducing ligand (TRAIL) levels of patients with bipolar disorder in manic episode, in remission and healthy controls, Psychiatry Research, vol.257, pp.338-383, 2017.
DOI : 10.1016/j.psychres.2017.07.067

I. Barbosa, G. Vaz, N. Rocha, R. Machado-vieira, M. Ventura et al., Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased in Bipolar Disorder, Clinical Psychopharmacology and Neuroscience, vol.15, issue.3, pp.269-75, 2017.
DOI : 10.9758/cpn.2017.15.3.269

E. Cheng, C. Armstrong, R. Galisteo, and J. Winkles, TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic, Frontiers in Immunology, vol.4, 2013.
DOI : 10.3389/fimmu.2013.00473

N. Wisniacki, L. Amaravadi, G. Galluppi, T. Zheng, R. Zhang et al., Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-TWEAK Monoclonal Antibody in Patients With Rheumatoid Arthritis, Clinical Therapeutics, vol.35, issue.8, pp.1137-1186, 2013.
DOI : 10.1016/j.clinthera.2013.06.008

G. Galluppi, N. Wisniacki, and C. Stebbins, Population pharmacokinetic and pharmacodynamic analysis of BIIB023, an anti-TNF-like weak inducer of apoptosis (anti-TWEAK) monoclonal antibody, British Journal of Clinical Pharmacology, vol.9, issue.1, pp.118-146, 2016.
DOI : 10.1186/1479-5876-9-13

U. Lassen, D. Meulendijks, L. Siu, V. Karanikas, M. Mau-sorensen et al., A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers, Clinical Cancer Research, vol.21, issue.2, pp.258-66, 2015.
DOI : 10.1158/1078-0432.CCR-14-1334